Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 79, Issue 5-6
April 2011
Issue Cover
All Issues
ISSN 0030-2414
EISSN 1423-0232

Journal Name Change

Vol. 1-20 (1948-1966) were published under the journal's former title Oncologia.

Oncology 2010, Vol. 79, No. 5-6

Editorial

Proposal to Rigorously Evaluate the Clinical Benefits Associated with a Novel Anti-Neoplastic Strategy outside the Confines of a Randomized Trial
Subject Area: Oncology
Maurie Markman
Oncology (2011) 79 (5-6): 321–323. https://doi.org/10.1159/000324716
View articletitled, Proposal to Rigorously Evaluate the Clinical Benefits Associated with a Novel Anti-Neoplastic Strategy outside the Confines of a Randomized Trial
Open the PDF for in another window

Clinical Translational Research

Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Subject Area: Oncology
Seung Il Kim; Joohyuk Sohn; Ja Seung Koo; Se Ho Park; Hyung Seok Park; Byeong Woo Park
Oncology (2011) 79 (5-6): 324–330. https://doi.org/10.1159/000322192
View articletitled, Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Open the PDF for in another window

Clinical Study

Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?
Subject Area: Oncology
A.A. Kotsori; S. Dolly; A. Sheri; M. Parton; N. Shaunak; S. Ashley; G. Walsh; S. Johnston; I.E. Smith
Oncology (2011) 79 (5-6): 331–336. https://doi.org/10.1159/000323175
View articletitled, Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?
Open the PDF for in another window
Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2)
Subject Area: Oncology
Bunzo Nakata; Akihito Tsuji; Yasushi Mitachi; Naoyuki Taenaka; Toshiki Kamano; Keisuke Oikawa; Naoyoshi Onoda; Mariko Kambe; Masahiro Takahashi; Tetsuhiko Shirasaka; Satoshi Morita; Junichi Sakamoto; Yukari Tanaka; Shigetoyo Saji; Kosei Hirakawa
Oncology (2011) 79 (5-6): 337–342. https://doi.org/10.1159/000323286
View articletitled, Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2)
Open the PDF for in another window
Participation in Cancer Clinical Trials as Viewed by Chinese Patients and Their Families
Subject Area: Oncology
Jun-ying Li; Chun-hua Yu; Yu Jiang
Oncology (2011) 79 (5-6): 343–348. https://doi.org/10.1159/000323325
View articletitled, Participation in Cancer Clinical Trials as Viewed by Chinese Patients and Their Families
Open the PDF for in another window
Local Recurrence after Breast Cancer Affects Specific Survival Differently according to Patient Age
Subject Area: Oncology
A. Courdi; J. Doyen; J. Gal; E. Chamorey
Oncology (2011) 79 (5-6): 349–354. https://doi.org/10.1159/000323483
View articletitled, Local Recurrence after Breast Cancer Affects Specific Survival Differently according to Patient Age
Open the PDF for in another window
Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib
Subject Area: Oncology
Katsuhiro Masago; Shiro Fujita; Yosuke Togashi; Young Hak Kim; Yukimasa Hatachi; Akiko Fukuhara; Hiroki Nagai; Kaoru Irisa; Yuichi Sakamori; Chiyuki Okuda; Tadashi Mio; Michiaki Mishima
Oncology (2011) 79 (5-6): 355–362. https://doi.org/10.1159/000323486
View articletitled, Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib
Open the PDF for in another window
Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy
Subject Area: Oncology
Seung Tae Kim; Kyong Hwa Park; Sang Cheul Oh; Jae Hong Seo; Sang Won Shin; Jun Suk Kim; Yeul Hong Kim
Oncology (2011) 79 (5-6): 363–369. https://doi.org/10.1159/000322498
View articletitled, Selection of a Patient Subgroup with Advanced Esophageal Squamous Carcinoma Who Could Benefit from Second-Line Chemotherapy
Open the PDF for in another window
Contrast-Enhanced Ultrasound: A Filter Role in AJCC Stage I/II Melanoma Patients
Subject Area: Oncology
Vincenzo De Giorgi; Alessia Gori; Marta Grazzini; Susanna Rossari; Gaetano Marino; Giovanni D’Elia; Emanuele Crocetti; Giuliana Roselli; Paolo Innocenti; Mario Dini; Torello Lotti
Oncology (2011) 79 (5-6): 370–375. https://doi.org/10.1159/000323494
View articletitled, Contrast-Enhanced Ultrasound: A Filter Role in AJCC Stage I/II Melanoma Patients
Open the PDF for in another window
Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy
Subject Area: Oncology
T. Aihara; K. Suemasu; H. Takei; Y. Hozumi; M. Takehara; T. Saito; S. Ohsumi; N. Masuda; Y. Ohashi
Oncology (2011) 79 (5-6): 376–381. https://doi.org/10.1159/000323489
View articletitled, Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy
Open the PDF for in another window
A Pilot Feasibility Study of TNFerade™ Biologic with Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer
Subject Area: Oncology
Deborah Citrin; Kevin Camphausen; Bradford J. Wood; Martha Quezado; John Denobile; James F. Pingpank; Richard E. Royal; H. Richard Alexander; Geoffrey Seidel; Seth M. Steinberg; Yvonne Shuttack; Steven K. Libutti
Oncology (2011) 79 (5-6): 382–388. https://doi.org/10.1159/000323488
View articletitled, A Pilot Feasibility Study of TNFerade™ Biologic with Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer
Open the PDF for in another window

Review

Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer
Subject Area: Oncology
Axel Grothey
Oncology (2011) 79 (5-6): 389–399. https://doi.org/10.1159/000323491
View articletitled, Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer
Open the PDF for in another window

Clinical Study

Anaplastic and Poorly Differentiated Thyroid Carcinoma: Therapeutic Strategies and Treatment Outcome of 52 Consecutive Patients
Subject Area: Oncology
P. Siironen; J. Hagström; H.O. Mäenpää; J. Louhimo; A. Heikkilä; I. Heiskanen; J. Arola; C. Haglund
Oncology (2011) 79 (5-6): 400–408. https://doi.org/10.1159/000322640
View articletitled, Anaplastic and Poorly Differentiated Thyroid Carcinoma: Therapeutic Strategies and Treatment Outcome of 52 Consecutive Patients
Open the PDF for in another window
Pandemic 2009 H1N1 Influenza in Patients with Hematopoietic Stem Cell Transplantation and Hematologic Malignancy: Single Center Experience
Subject Area: Oncology
Emre Tekgündüz; Meltem Kurt Yüksel; Çiğdem Erbay; Bilgin Arıbaş; Çiğdem Özdilekcan; Hülya Arslan; Şerife Koçubaba; Itır Demiriz; Ayşegül Tetik; Kemal Arda; Fevzi Altuntaş
Oncology (2011) 79 (5-6): 409–414. https://doi.org/10.1159/000320789
View articletitled, Pandemic 2009 H1N1 Influenza in Patients with Hematopoietic Stem Cell Transplantation and Hematologic Malignancy: Single Center Experience
Open the PDF for in another window
Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study
Subject Area: Oncology
Giuseppe Colucci; Francesco Giuliani; Carlo Garufi; Rodolfo Mattioli; Luigi Manzione; Antonio Russo; Massimo Lopez; Paola Parrella; Stefania Tommasi; Massimiliano Copetti; Bruno Daniele; Salvatore Pisconti; Guido Tuveri; Nicola Silvestris; Evaristo Maiello
Oncology (2011) 79 (5-6): 415–422. https://doi.org/10.1159/000323279
View articletitled, Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study
Open the PDF for in another window
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Subject Area: Oncology
Hajime Asahina; Satoshi Oizumi; Akira Inoue; Ichiro Kinoshita; Takashi Ishida; Yuka Fujita; Noriaki Sukoh; Masao Harada; Makoto Maemondo; Yasuo Saijo; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Toshihiro Nukiwa; Masaharu Nishimura; on behalf of the Hokkaido Lung Cancer Clinical Study Group
Oncology (2011) 79 (5-6): 423–429. https://doi.org/10.1159/000326488
View articletitled, Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Open the PDF for in another window

Clinical Translational Research

BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer
Subject Area: Oncology
Caroline Brunetto de Farias; Denis Broock Rosemberg; Tiago Elias Heinen; Patricia Koehler-Santos; Ana Lucia Abujamra; Flávio Kapczinski; Algemir Lunardi Brunetto; Patricia Ashton-Prolla; Luise Meurer; Maurício Reis Bogo; Daniel C. Damin; Gilberto Schwartsmann; Rafael Roesler
Oncology (2011) 79 (5-6): 430–439. https://doi.org/10.1159/000326564
View articletitled, BDNF/TrkB Content and Interaction with Gastrin-Releasing Peptide Receptor Blockade in Colorectal Cancer
Open the PDF for in another window

Clinical Study

A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53
Subject Area: Oncology
Jong Jin Oh; Sang Hyun Ji; Don Kyoung Choi; In Hyuk Gong; Tae Heon Kim; Dong Soo Park
Oncology (2011) 79 (5-6): 440–446. https://doi.org/10.1159/000327214
View articletitled, A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53
Open the PDF for in another window

Further Section

Acknowledgement to the Reviewers
Subject Area: Oncology
Oncology (2011) 79 (5-6): 447–448. https://doi.org/10.1159/000328395
View articletitled, Acknowledgement to the Reviewers
Open the PDF for in another window
Author Index Vol. 79, 2010
Subject Area: Oncology
Oncology (2011) 79 (5-6): 449–450. https://doi.org/10.1159/000328401
View articletitled, Author Index Vol. 79, 2010
Open the PDF for in another window
Subject Index Vol. 79, 2010
Subject Area: Oncology
Oncology (2011) 79 (5-6): 451–452. https://doi.org/10.1159/000328402
View articletitled, Subject Index Vol. 79, 2010
Open the PDF for in another window
Contents Vol. 79, 2010
Subject Area: Oncology
Oncology (2011) 79 (5-6): I–IV. https://doi.org/10.1159/000328400
View articletitled, Contents Vol. 79, 2010
Open the PDF for in another window
Immunotherapy plus chemotherapy for patients with EGFR-mutated non-squamous cell lung cancer for disease progression after EGFR tyrosine-kinase inhibitor: A meta-analysis of randomized controlled trials
Clinical effects and safety of intra-arterial infusion chemotherapy with lipiodol versus intra-arterial infusion chemotherapy alone for treatment of advanced hepatocellular carcinoma
Dose-reduction of bevacizumab in atezolizumab plus bevacizumab therapy extends treatment duration with disease control in patients with hepatocellular carcinoma
The usefulness of serum interleukin-6 as a predictor of response to atezolizumab plus bevacizumab combination treatment in hepatocellular carcinoma
  • Online ISSN 1423-0232
  • Print ISSN 0030-2414
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal